Mast Therapeutics (NASDAQ:SVRA) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.
SVRA has been the topic of a number of other reports. Zacks Investment Research cut Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. Canaccord Genuity upped their price objective on Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 30th. Jefferies Group initiated coverage on Mast Therapeutics in a report on Friday, September 22nd. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Roth Capital reiterated a “buy” rating and issued a $40.00 price objective on shares of Mast Therapeutics in a report on Wednesday, September 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $21.30.
Mast Therapeutics (SVRA) opened at $13.49 on Friday. Mast Therapeutics has a twelve month low of $4.60 and a twelve month high of $16.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15.
WARNING: “ValuEngine Downgrades Mast Therapeutics (SVRA) to Strong Sell” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/03/valuengine-downgrades-mast-therapeutics-svra-to-strong-sell.html.
About Mast Therapeutics
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
What are top analysts saying about Mast Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mast Therapeutics Inc. and related companies.